Analysts Set Insmed, Inc. (NASDAQ:INSM) PT at $211.00

Insmed, Inc. (NASDAQ:INSM) has earned an average recommendation of “Moderate Buy” from the twenty-five research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, twenty-three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $211.0455.

Several analysts have commented on the stock. Truist Financial decreased their price target on shares of Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Leerink Partners lifted their target price on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. JPMorgan Chase & Co. dropped their price target on Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a research note on Monday, June 8th. Finally, Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $166.00 to $212.00 in a research note on Monday, March 30th.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the sale, the chief financial officer owned 69,082 shares of the company’s stock, valued at $7,065,016.14. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 2,370 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90. Following the transaction, the chief operating officer owned 98,603 shares of the company’s stock, valued at $10,084,128.81. This trade represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 54,590 shares of company stock valued at $5,793,738. 2.10% of the stock is owned by company insiders.

Institutional Trading of Insmed

Hedge funds have recently made changes to their positions in the business. CIBC Private Wealth Group LLC boosted its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Insmed by 10.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 69 shares in the last quarter. ORG Partners LLC raised its holdings in Insmed by 12.7% in the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares during the period. Private Advisor Group LLC raised its holdings in Insmed by 1.8% in the 1st quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock worth $777,000 after purchasing an additional 82 shares during the period. Finally, Glenmede Trust Co. NA boosted its position in Insmed by 5.4% during the first quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 98 shares in the last quarter.

Insmed Trading Up 0.8%

Shares of INSM opened at $108.32 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a 50 day simple moving average of $105.72 and a two-hundred day simple moving average of $135.91. The firm has a market cap of $23.48 billion, a P/E ratio of -18.84 and a beta of 0.78.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the firm earned ($1.42) earnings per share. The company’s quarterly revenue was up 229.7% compared to the same quarter last year. On average, equities analysts expect that Insmed will post -2.43 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.